If left untreated by anti-fibrotic medications, idiopathic pulmonary fibrosis (IPF) has a 50% mortality rate after three years, according to a recent observational study using real-world data. This is compared with a 26–31% mortality rate among IPF patients taking available anti-fibrotics, such as Esbriet (pirfenidone) and Ofev…
News
Treatment with either Ofev (nintedanib) or Esbriet (pirfenidone) — both antifibrotic therapies, but with different mechanisms of action — “offers protection” and can slow lung function decline in people with pulmonary fibrosis (PF), according to a new analysis. Moreover, the results showed that these medications can significantly reduce…
Pulmonary Fibrosis News brought you daily coverage throughout 2021 of the latest scientific findings, treatment developments, and clinical trials related to pulmonary fibrosis (PF). As a reminder of what mattered most to you during the past year, here are the top 10 most-read articles of 2021, with a brief…
Idiopathic pulmonary fibrosis (IPF) patients with increased formation of type VI collagen — a major extracellular matrix (ECM) molecule involved in wound healing and scarring — are at higher risk of having progressive disease, a real-world study shows. Also, type VI collagen breakdown tended to increase in patients with progressive…
The glam and glitzy affair that is Broadway Belts for PFF! is set for March 7 in New York City. And for the first time, supporters can experience the event interactively from home. The 12th annual event — the single largest fundraiser for the Pulmonary Fibrosis Foundation (PFF) —…
The University of Calgary is developing a clinical tool to help identify the environmental and occupational risks of pulmonary fibrosis (PF), an undertaking that could lead to a deeper understanding of how the disease takes hold and aid in developing treatments. During the 18-month project, supported by the Three…
A $5 million gift to the University of South Florida (USF) from the philanthropist and entrepreneur Timothy Ubben will be used to create the Ubben Family Center for Pulmonary Fibrosis, dedicated to disease research. The center will be located at the USF Health Morsani College of Medicine in Tampa. This…
Pinocembrin, a compound isolated from eucalyptus trees, significantly reduced the signs and symptoms of lung damage in a sheep model of pulmonary fibrosis (PF), a study demonstrated. “We found that pinocembrin improved lung function, attenuated [eased the effect of] lung inflammation, and decreased overall pathology scores compared to damaged…
AstraZeneca has added a novel target for idiopathic pulmonary fibrosis (IPF) to its portfolio, which was uncovered using BenevolentAI’s artificial intelligence-driven medication discovery platform. “The cause of IPF is largely unknown and the exact mechanisms involved in the progression of IPF remain elusive,” Anne Phelan, PhD, chief scientific…
A lyric-writing challenge has culminated in a new song, “Breath of Life (Para Don Berna),” that is being debuted by “American Idol” winner Jordin Sparks and New York Yankees veteran and Latin Grammy nominee Bernie Williams to increase awareness and promote the early diagnosis of idiopathic pulmonary fibrosis (IPF).
Your PF Community
Recent Posts
- Gut bacteria B. adolescentis may be new preventive treatment for PF January 7, 2026
- On my diagnosis journey, I felt like I was moving in slow motion January 6, 2026
- Amid a sea of data, the PF community is critical in the search for a cure December 23, 2025
- FDA approves Jascayd for adults with progressive pulmonary fibrosis December 23, 2025
- Oral therapy GRI-0621 boosts lung function, repairs tissue in IPF: Data December 17, 2025
